A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
NCT07434050 on ClinicalTrials.gov · last registry update 2026-08-28
A small phase 3 — 140 participants, against a typical 424. Due to report 19 June 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Change from baseline in Apnea-Hypopnea Index (AHI). Sponsors move these dates routinely; any movement since this site started watching is listed below. ecnoglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P3
- Drug
- ecnoglutide
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 140
- Started
- 2026-03-02
- Primary completion
- 2028-06-19 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from baseline in Apnea-Hypopnea Index (AHI)
Conditions studied
OSA - Obstructive Sleep Apnea · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the ecnoglutide page for this molecule’s full trial and approval history.